- Definition

Represents the amount of additional payments to be made by the entity upon the achievement of certain development and commercialization milestones under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementAdditionalPaymentsToBeMadeUponAchievementOfCertainDevelopmentAndCommercializationMilestones
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the further license fee payable upon the achievement of certain clinical and regulatory milestones under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementFurtherLicenseFee
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the initial license fee under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementInitialLicenseFee
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the nonrefundable payments made by the entity under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementNonrefundablePaymentMade
Namespace Prefix:	rdus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the period for payment of royalties after the date of the first commercial sale in such country of any product including the licensed compound.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementPeriodAfterDateOfFirstCommercialSaleOfProductForPaymentOfRoyalties
Namespace Prefix:	rdus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty as a percentage of net sales of any product by the Company or its sublicenses under the collaborative agreements.

+ References

No definition available.

+ Details

Name:	rdus_CollaborativeArrangementRoyaltyRate
Namespace Prefix:	rdus_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	rdus_CollaborativeArrangementsTypeOfAgreementAxis=rdus_EisaiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_TypeOfAgreementAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_CollaborativeArrangementsTypeOfAgreementAxis=rdus_SCRASSASAndAffiliatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rdus_TypeOfAgreementAxis=rdus_SublicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements (Details) $ in Thousands, € in Millions		3 Months Ended		7 Months Ended	9 Months Ended		12 Months Ended
License Agreements (Details) $ in Thousands, € in Millions	Mar. 09, 2015 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2016 EUR (€)	Dec. 31, 2006 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2016 EUR (€)	Dec. 31, 2005 USD ($)
Eisai \| License Agreement
License Agreements
Period after the date of the first commercial sale of the product for license expiration					10 years	10 years
Initial license fee paid	$ 400			$ 500
Eisai \| License Agreement \| Minimum
License Agreements
Payments to be made upon achievement of certain clinical and regulatory milestones					$ 1,000
Eisai \| License Agreement \| Maximum
License Agreements
Payments to be made upon achievement of certain clinical and regulatory milestones					$ 20,000
Clinical Trial Services Agreement \| Ipsen
License Agreements
Nonrefundable, non-creditable payment							$ 250
Royalty rate (as a percent)					5.00%	5.00%
Payments to be made upon achievement of certain clinical and regulatory milestones		$ 3,300	€ 3.0
Clinical Trial Services Agreement \| Ipsen \| Minimum
License Agreements
Additional payments to be made upon achievement of certain development and commercialization milestones					$ 11,200	€ 10.0
Period after the date of the first commercial sale of the product for license expiration					10 years	10 years
Clinical Trial Services Agreement \| Ipsen \| Maximum
License Agreements
Additional payments to be made upon achievement of certain development and commercialization milestones					$ 40,400	€ 36.0
Clinical Trial Services Agreement \| Ipsen \| Sublicense Agreement
License Agreements
Period after the date of the first commercial sale of the product for license expiration					10 years	10 years